Immunome, Inc.
Status: Publicly traded
Direct answer
Immunome, Inc. is publicly traded on NASDAQ under the ticker IMNM.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan...
Can you invest in Immunome, Inc.?
Yes. Immunome, Inc. trades publicly on NASDAQ as IMNM.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Immunome, Inc.
Detailed equity research is provided by MarketSnap.